Trial Details
COMPLETEDBasic Information
| Clinical ID | c1793 |
|---|---|
| Identifier | NCT03345836 |
| Trial Title | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Crohn's Disease |
| Interventions | DRUG: Matching Placebo for Upadacitinib|DRUG: Upadacitinib |
Participant Information
| Sponsor | AbbVie |
|---|---|
| City | Mobile |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2017-11-29 |
|---|---|
| Primary Completion Date | 2021-08-11 |
| Completion Date | 2021-08-11 |